Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 10/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23698900 | 0.91 | CHRM1 (0.49) | CHRM1CYP11B1CYP11B2GRM2KCNJ1 | |
| SCHEMBL23698817 | 0.90 | CHRM1 (0.47) | CHRM1GRM2 | |
| SCHEMBL21834493 | 0.85 | CHRM1 (0.44) | CHRM1GRM2MET | |
| SCHEMBL30428197 | 0.83 | CHRM1 (0.49) | CHRM1CYP11B1CYP11B2GRM2KCNJ1 | |
| SCHEMBL21873365 | 0.83 | CHRM1 (0.49) | CHRM1CYP11B1CYP11B2GRM2KCNJ1 | |
| SCHEMBL23713268 | 0.82 | CYP11B1 (0.45) | CHRM1CYP11B1CYP11B2GRM2KCNJ1 | |
| SCHEMBL21834470 | 0.82 | KAT6A (0.35) | CHRM1 | |
| SCHEMBL23698814 | 0.82 | CHRM1 (0.76) | CHRM1 | |
| SCHEMBL23698891 | 0.81 | BRD4 (0.36) | CHRM1 | |
| SCHEMBL23698833 | 0.79 | CHRM1 (0.47) | CHRM1GRM2STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162864-B2 | Condensed-cyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-12-10 | — | — | US | disclosed |
| EP-3858823-A1 | CONDENSED-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162864-B2 | Condensed-cyclic compound | SLC10A2, VIP, AVPR2 | CHRM1 576/4885CYP11B1 747/4885CYP11B2 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.